腫瘍内科 抄読会
帝京大学医学部内科学講座 腫瘍内科では、毎週月曜日に、最新のがん医療、がん研究に関するトピックに関する抄読会を開催しています。
ご興味のある方はぜひご参加ください。
2022年度 開催記録
※横にスクロールできます。
| 日付 | 担当 | 論文タイトル | 掲載雑誌 |
|---|---|---|---|
| 4月4日 | 本田 | Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival? |
Ann Surg Oncol (2022) 29:1807–1814 |
| 4月11日 | 研修医 岩佐 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastrooesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial |
Lancet Oncol . 2022 Feb;23(2):234-247. |
| 4月18日 | 風張 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | Lancet Oncol. 2020 May ; 21(5): 671–684. |
| 4月25日 | 市川 | Effectiveness of PD-(L)1 inhibitors alone or in combination with platinumdoublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data |
Ann Oncol . 2022 May;33(5):511-521. |
| 5月23日 | 市川 | Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative |
J Clin Oncol . 2022 May 1;40(13):1414-1427. |
| 7月4日 | 風張 | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC |
JTO Clin Res Rep . 2020 Mar 4;1(2):100020 |
| 8月1日 | 本田 | Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis |
Lancet Oncol 2022 Published Online |
| 8月15日 | 石原 | Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials |
J Thorac Oncol . 2022 Jun;17(6):758-767. |
| 8月22日 | 研修医 星谷 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
N Engl J Med 2022;387:9-20. |
| 9月12日 | 風張 | Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies |
Autoimmun Rev . 2020 Dec;19(12):102687. |
| 10月24日 | 市川 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer |
N Engl J Med 2022;386:1973-85. |
| 11月7日 | 風張 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | N Engl J Med 2022;387:9-20. |
| 11月21日 | 本田 | The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study |
Front Immunol . 2022 Sep 9;13:975246 |
| 12月5日 | 市川 | Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) |
J Thorac Oncol . 2022 Dec;17(12):1404-1414. |
| 2月6日 | 研修医 佐藤 | Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma | N Engl J Med 2022;387:2113-25. |
2020年度 開催記録
※横にスクロールできます。
| 日付 | 担当 | 論文タイトル | 掲載雑誌 |
|---|---|---|---|
| 7月20日 | 丹澤 | Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study |
J Clin Oncol 38:2369-2379. |
| 8月3日 | 春山 | Treatment Decisions for Advanced Non‑Squamous Non‑Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy |
Patient. 2019 Apr;12(2):223-233. |
| 8月24日 | 研修医1年 | 症例報告 | |
| 9月14日 | 落合 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan |
Lung Cancer 129 (2019) 55–62 |
| 10月5日 | 風張 | 内科地方会予演会 | |
| 10月19日 | 研修医1年 | ||
| 11月2日 | 市川 | 肺癌学会予演会 |
2019年度 開催記録
※横にスクロールできます。
| 日付 | 担当 | 論文タイトル | 掲載雑誌 |
|---|---|---|---|
| 4月1日 | オリエンテーション | ||
| 4月8日 | 本田 | Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study |
Lancet Oncol 2018; 19: 1579–89 |
| 4月15日 | 研修医1年①星野 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer |
N Engl J Med 2019;380:1226-34. |
| 4月22日 | 研修医1年②平田 | Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial |
Lancet Oncol 2019 May;20(5):625-635. |
| 5月13日 | 上松先生の講義 | EGFR-TKIの爪囲炎のケア | |
| 5月27日 | 太田 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised,open-label, controlled, phase 3 trial | Lancet 2019; 393: 1819–30 |
| 6月3日 | 坂本 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-quamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial |
Lancet Oncol 2019 Published Online May 20, 2019 |
| 6月10日 | 渡邊 | Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database |
JAMA. 2019;321(14):1391-1399. |
| 6月17日 | 田上 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | J Clin Oncol. 2019 Jun 2:JCO1900934 |
| 6月24日 | 研修医1年 風張 | Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2):a multicentre, open-label, randomised, non-comparative,phase 2 trial | Lancet Oncol 2019; 20: 239–53 |
| 7月1日 | 落合予演会 | ||
| 7月8日 | 市川 | ASCO報告 | |
| 7月29日 | 石原 | Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors | Journal of Thoracic Oncology Vol. 14 No. 7: 1244-1254 |
| 8月5日 | 丹澤 | ASCO報告 | |
| 8月26日 | 研修医1年中島 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568):Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | J Clin Oncol 37:992-1000. |
| 9月2日 | 春山 | Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial |
TheOncologist 2017;22:1–8 |
| 10月7日 | 落合 | Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial | Ann Oncol. 2019 Aug 27. |
| 10月21日 | 本田 | Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study |
J Clin Oncol 37:1558-1565. |
| 11月25日 | 研修医2年 青木 | Association between waist circumference and risk of colorectal neoplasia in normal-weight adults |
J Gastroenterol Hepatol. 2019 Jun 27. |
| 12月2日 | 太田 | Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled,open-label, phase 3 trial | Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6 |
| 12月23日 | 研修医1年 菅 | Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial |
Lancet Oncol. 2018 Nov;19(11):1437-1448. |
| 1月27日 | 市川 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial | Lancet. 2019 Oct 4. pii: S0140-6736(19)32222-6. |
| 2月3日 | 坂本 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer |
N Engl J Med 2018;379:2108-21. |
| 2月10日 | 渡邊 | Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer | Gastroenterology. 2019 Dec 19. pii: S0016-5085(19)41937-9 |
後期研修医募集